The CONFORM Pivotal Trial
An Evaluation of the Safety and Effectiveness of the Conformal CLAAS System for Left Atrial Appendage Occlusion
1 other identifier
interventional
1,600
5 countries
88
Brief Summary
The CLAAS® device will be evaluated for safety and efficacy by establishing its performance is non-inferior to the commercially available WATCHMAN® and Amulet™ left atrial appendage closure devices in patients with non-valvular atrial fibrillation. Patients who are eligible for the trial will be randomized to receive either the CLAAS device or the WATCHMAN or Amulet™ devices and will be followed for 5 years after device implant.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable atrial-fibrillation
Started May 2022
Longer than P75 for not_applicable atrial-fibrillation
88 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 24, 2021
CompletedFirst Posted
Study publicly available on registry
December 7, 2021
CompletedStudy Start
First participant enrolled
May 26, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2031
May 6, 2026
April 1, 2026
6 years
November 24, 2021
May 5, 2026
Conditions
Outcome Measures
Primary Outcomes (2)
Procedure-related complications, all-cause death, major bleeding
The primary safety endpoint is a composite of 1) major procedure-related complications including a) cardiac perforation, b) pericardial effusion requiring drainage, c) ischemic stroke, d) device embolization, and e) major vascular complications, or 2) major bleeding, or 3) all-cause death
12 months
Ischemic stroke and systemic embolism
The primary effectiveness endpoint is a composite of ischemic stroke and systemic embolism through 18 months.
18 months
Secondary Outcomes (6)
Procedure-related complications, all-cause death, major bleeding
5 years
Device Success
Procedure
Technical success
45 days
Procedure success
7 Days
Embolic Events
12 Months, 18 Months
- +1 more secondary outcomes
Study Arms (2)
CLAAS
EXPERIMENTALTranscatheter left atrial occluder
WATCHMAN / Amulet
ACTIVE COMPARATORTranscatheter left atrial occluder
Interventions
WATCHMAN left atrial appendage closure device / Amulet left atrial appendage occluder
Eligibility Criteria
You may qualify if:
- Male or non-pregnant female aged ≥18 years
- Documented non-valvular AF (paroxysmal, persistent, or permanent)
- High risk of stroke or systemic embolism, defined as CHA2DS2-VASc score of ≥ 3
- Has an appropriate rationale to seek a non-pharmacologic alternative to long-term oral anticoagulation
- Deemed by the site investigator to be suitable for short term oral anticoagulation therapy but deemed less favorable for long-term oral anticoagulation therapy.
- Deemed appropriate for LAA closure by the site investigator and a clinician not a part of the procedural team using a shared decision-making process in accordance with standard of care
- Able to comply with the protocol-specified medication regimen and follow-up evaluations
- The subject (or legally authorized representative, where allowed) has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent approved by the appropriate institutional review board (IRB)/Regional Ethics Board (REB)/Ethics Committee (EC).
You may not qualify if:
- Pregnant or nursing patients and those who plan pregnancy in the period up to one year following the index procedure. Female patients of childbearing potential must have a negative pregnancy test (per site standard test) within 7 days prior to index procedure.
- Anatomic conditions that would prevent performance of an LAA occlusion procedure (e.g., atrial septal defect (ASD) requiring closure, high-risk patent foramen ovale (PFO) requiring closure, a highly mobile inter-atrial septal aneurysm precluding a safe TSP, presence of a PFO/ASD closure device, history of surgical ASD repair or history of surgical LAAO closure)
- Atrial fibrillation that is defined by a single occurrence or that is transient or reversible (e.g., secondary thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures)
- A medical condition (other than atrial fibrillation) that mandates long-term oral anticoagulation (e.g., history of unprovoked deep vein thrombosis or pulmonary embolism, or prosthetic mechanical heart valve)
- History of bleeding diathesis or coagulopathy, or patients in whom antiplatelet and/or anticoagulant therapy is contraindicated
- Documented active systemic infection
- Symptomatic carotid artery disease (defined as \>50% stenosis with symptoms of ipsilateral transient or visual TIA evidenced by amaurosis fugax, ipsilateral hemispheric TIAs or ipsilateral stroke); if subject has a history of carotid stent or endarterectomy the subject is eligible if there is \<50% stenosis noted at the site of prior treatment
- Recent (within 30 days of index procedure) or planned (within 60 days post-procedure) cardiac or major non-cardiac interventional or surgical procedure
- Recent (within 30 days of index procedure) stroke or transient ischemic attack
- Recent (within 30 days of index procedure) myocardial infarction
- Vascular access precluding delivery of implant with catheter-based system
- Severe heart failure (New York Heart Association Class IV)
- Prior cardiac transplant, history of mitral valve replacement or transcatheter mitral valve intervention, or any prosthetic mechanical valve implant
- Renal insufficiency, defined as estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m2 (by the Modification of Diet in Renal Disease equation)
- Platelet count \<75,000 cells/mm3 or \>700,000 cells/mm3, or white blood cell count \<3,000 cells/mm3
- +14 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (88)
Grandview Medical Center
Birmingham, Alabama, 35243, United States
Banner University Medical Center Phoenix
Phoenix, Arizona, 85006, United States
Abrazo Arizona Heart Hospital
Phoenix, Arizona, 85016, United States
Arizona Heart Arrhythmia Associates
Phoenix, Arizona, 85018, United States
HonorHealth
Scottsdale, Arizona, 85258, United States
Pima Heart & Vascular
Tucson, Arizona, 85719, United States
St. Bernard's Medical Center
Jonesboro, Arkansas, 72401, United States
Loma Linda University Health
Loma Linda, California, 92354, United States
Huntington Hospital
Pasadena, California, 91105, United States
Pacific Heart Institute
Santa Monica, California, 90405, United States
Community Memorial Hospital Ventura
Ventura, California, 93003, United States
South Denver Cardiology Associates
Littleton, Colorado, 80120, United States
Hartford Health Care St. Vincent's Medical Center
Bridgeport, Connecticut, 06606, United States
MedStar Washington Hospital Center
Washington D.C., District of Columbia, 20010, United States
Ascension St. Vincent's Jacksonville
Jacksonville, Florida, 32204, United States
Largo Medical Center
Largo, Florida, 33770, United States
Baptist Hospital of Miami
Miami, Florida, 33176, United States
AdventHealth Orlando
Orlando, Florida, 32803, United States
Baptist Health Care - Pensacola
Pensacola, Florida, 32503, United States
Sarasota Memorial Health Care System
Sarasota, Florida, 34239, United States
AdventHealth Tampa
Tampa, Florida, 33613, United States
USF - Tampa General Hospital
Tampa, Florida, 33620, United States
Piedmont Health Institute
Atlanta, Georgia, 30309, United States
Emory University
Atlanta, Georgia, 30342, United States
Northside Hospital, Inc
Atlanta, Georgia, 30342, United States
WellStar Kennestone Hospital
Marietta, Georgia, 30062, United States
Midwest Cardiovascular Institute
Naperville, Illinois, 60540, United States
Ascension St. Vincent - Carmel, IN
Indianapolis, Indiana, 46260, United States
University of Iowa
Iowa City, Iowa, 52242, United States
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
Terrebone - Cardiovascular Institute of the South
Houma, Louisiana, 70360, United States
Medstar Union Memorial Hospital
Baltimore, Maryland, 21218, United States
Johns Hopkins University
Baltimore, Maryland, 21287, United States
Lahey Hospital & Medical Centeer
Burlington, Massachusetts, 01805, United States
Baystate Medical Center
Springfield, Massachusetts, 01199, United States
Henry Ford St. John Hospital
Detroit, Michigan, 48236, United States
Corewell Health
Grand Rapids, Michigan, 49503, United States
Henry Ford Providence Southfield Hospital
Southfield, Michigan, 48075, United States
M Health Fairview St. John's Hospital
Maplewood, Minnesota, 55109, United States
CentraCare Heart and Vascular Center
Saint Cloud, Minnesota, 56303, United States
North Mississippi Medical Center
Tupelo, Mississippi, 38801, United States
Saint Luke's Hospital of Kansas City
Kansas City, Missouri, 64111, United States
Kansas City Cardiac Arrhythmia Research, LLC
Overland, Missouri, 66211, United States
CHI Health / CommonSpirit Research Institute
Omaha, Nebraska, 68124, United States
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
Catholic Medical Center
Manchester, New Hampshire, 03102, United States
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
Cooper University - Heart House
Haddon Heights, New Jersey, 08104, United States
New Mexico Heart Institute
Albuquerque, New Mexico, 87102, United States
Albany Medical Center / Capital Cardiology Associates
Albany, New York, 12208, United States
University of Buffalo / Kaleida Health
Buffalo, New York, 14203, United States
Mount Sinai Hospital
New York, New York, 10029, United States
Mission Hospital
Asheville, North Carolina, 28801, United States
TriHealth
Cincinnati, Ohio, 45242, United States
Ohio Health Research Institute
Columbus, Ohio, 43214, United States
ProMedica Toledo Hospital
Toledo, Ohio, 43606, United States
Legacy Emanuel Hospital and Health
Portland, Oregon, 97228, United States
UPMC Harrisburg
Mechanicsburg, Pennsylvania, 17050, United States
Lankenau Heart Institute
Wynnewood, Pennsylvania, 19096, United States
Lifespan Health System
Providence, Rhode Island, 02903, United States
Prisma Health
Columbia, South Carolina, 29203, United States
HCA Grand Strand
Myrtle Beach, South Carolina, 29572, United States
Trident Medical Center
North Charleston, South Carolina, 29406, United States
Erlanger Health System
Chattanooga, Tennessee, 37403, United States
Tennova Healthcare - Turkey Creek Medical Center
Knoxville, Tennessee, 37934, United States
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
Houston Methodist
Houston, Texas, 77030, United States
Memorial Hermann Memorial City Medical Center
Houston, Texas, 77094, United States
CHRISTUS Health
Tyler, Texas, 75701, United States
Sentara Norfolk
Norfolk, Virginia, 23507, United States
Virginia Commonwealth University
Richmond, Virginia, 23219, United States
Chippenham Hospital
Richmond, Virginia, 23225, United States
Carilion Clinic
Roanoke, Virginia, 24014, United States
Virginia Mason Medical Center
Seattle, Washington, 98101, United States
West Virginia University
Morgantown, West Virginia, 26506, United States
Bellin Health
Green Bay, Wisconsin, 54301, United States
Nemocnice Na Homolce
Prague, 150 00, Czechia
CHU de Bordeaux
Bordeaux, 33604, France
CHU La Timone, Marseille
Marseille, 13005, France
Institut Cardiovasculaire Paris Sud
Massy, 91300, France
CHU de Toulouse
Toulouse, 31059, France
Clinique Pasteur, Toulouse
Toulouse, 31076, France
Chapidze Heart Disease Center
Tbilisi, Georgia
Israeli-Georgian Medical Research Clinic Helsicore
Tbilisi, Georgia
Tbilisi Heart and Vascular Clinic
Tbilisi, Georgia
Tbilisi Heart Center
Tbilisi, Georgia
Republican Specialized Center for Surgery named after V. Vakhidov
Chilanzar, Tashkent, 100115, Uzbekistan
AKFA Medline
Olmazor, Tashkent, 100211, Uzbekistan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
William Gray, M.D.
Lankenau Heart Institute
- PRINCIPAL INVESTIGATOR
Shephal Doshi, M.D.
Pacific Heart Institute
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 24, 2021
First Posted
December 7, 2021
Study Start
May 26, 2022
Primary Completion (Estimated)
June 1, 2028
Study Completion (Estimated)
December 1, 2031
Last Updated
May 6, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will not share